Novartis has agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront, to enhance its oncology portfolio with Myricx's novel antibody-drug conjugate (ADC) payloads. Myricx Bio specializes in a first-in-class N-myristoyltransferase inhibitor (NMTi) platform, offering a new mechanism to target solid tumors and overcome limitations of current ADC treatments. The acquisition aims to accelerate development of these innovative cancer therapies, with the deal expected to close in the second half of 2026 pending regulatory approvals.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

Novartis has agreed to acquire Myricx Bio, a UK-based oncology company developing novel antibody-drug conjugates (ADCs), for up to $1.5 billion including $1.1 billion upfront. This acquisition combines Novartis's oncology expertise with Myricx Bio's ...

Company Fundamentals

Bullish

1 hour ago

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App